novo nordisk glp 1 pill Finds Medicare Patients Prefer GLP-1 Over Shot for Weight Loss Novo Nordisk files lawsuit against

In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: Injectable GLP-1s 2025 Ozempic for T2DM and peripheral artery disease (PAD) 2H 2025 Wegovy for heart failure with preserved ejection fraction (HFpEF) and obesity Oral GLP-1s October 2025 new indication for oral Rybelsus for secondary CV risk reduction 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape

Molecular Cancer Research 22(4), 2024

For in vitro studies, various groups have utilized a broad range of TGF- concentrations over different time intervals, as summarized in Table 1

2011 Apr 30;377(9776):1494